Results 101 to 110 of about 21,372 (208)

The role of the adenosinergic pathway in resistance to hypomethylating agents in patients with high‐risk myelodysplastic syndromes

British Journal of Haematology, EarlyView.
George Vrachiolias, Eleftheria Lamprianidou, Athanasios Tasis, Theodoros Spyropoulos, Despoina Dimitriou, Chryssa Kymparidou, Christina Misidou, Konstantinos Liapis, Emmanouil Spanoudakis, Maria Koffa, Menelaos Papoutselis, Iliana Stamatiou, Elsa Bernard, Elli Papaemmanuil, Ioannis Mitroulis, Ioannis Kotsianidis   +15 more
wiley   +1 more source

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3‐ITD–Positive AML

Cancer Science, EarlyView.
ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba, Toshihiro Miyamoto, Senji Kasahara, Yoshikane Kikushige, Takahiro Maeda, Goichi Yoshimoto, Shuichi Ota, Akio Saito, Yuho Najima, Hiroki Hosoi, Daigo Niiya, Koji Kato, Koji Nagafuji, Takashi Akasaka, Tomohiko Kamimura, Atsushi Takita, Maiko Narahara, Tadashi Toki, Koichi Iwanaga, Koji Yonemoto, Mine Harada, Koichi Akashi   +21 more
wiley   +1 more source

Effects of venetoclax on oxidative phosphorylation in MOLM-13 cells

Acute myeloid leukemia (AML) represents the most prevalent type of acute leukemia in adults and poses a substantial clinical challenge due to its elevated mortality rates and the rapid development of resistance to available therapies.
Stoschek, Karoline Maria
core   +1 more source

Understanding Genomic Mechanisms of Venetoclax Resistance in Haematological Malignancy

, 2022
© 2022 Piers Alexander BlomberyResistance to targeted therapies is an important cause of treatment failure in haematological malignancy. Venetoclax is one of the most effective targeted agents in chronic lymphocytic leukaemia (CLL) and lymphoid ...
Blombery, Piers Alexander
core   +1 more source

Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate

Scientific Reports
Venetoclax has been approved recently for treatment of Acute myeloid leukemia (AML). Venetoclax is a BH3-mimetic and induces apoptosis via Bcl-2 inhibition. However, venetoclax’s effect is still restrictive and a novel strategy is needed.
Renshi Kawakatsu, Kenjiro Tadagaki, Kenta Yamasaki, Tatsushi Yoshida   +3 more
doaj   +1 more source

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy

British Journal of Haematology, EarlyView.
Isacco Ferrarini, Daniela Estefania Banegas, Andrea Bernardelli, Alessia Moioli, Francesca Maria Quaglia, Ester Lovato, Anna Maria Frustaci, Massimiliano Postorino, Davide Facchinelli, Monica Tani, Francesca Cibien, Chandrakala Toldo, Elisa Lucchini, Roberto Marasca, Marzia Varettoni, Chiara Rusconi, Lucia Farina, Andrea Visentin, Riccardo Moia, Carlo Visco   +19 more
wiley   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

Venetoclax Resistance in Acute Myeloid Leukemia

Venetoclax is a BH3-mimetics agent interacting with the anti-apoptotic protein BCL2, facilitating cytochrome c release from mitochondria, subsequent caspases activation, and cell death.
Marie-Anne Hospital, Norbert Vey, Vey, Norbert, Yves Collette, Sylvain Garciaz, Garciaz, Sylvain, Hospital, Marie-Anne, Collette, Yves   +7 more
core   +1 more source

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

Nature Communications, 2019
The BCL-2 mutation G101V reduces venetoclax affinity and confers drug resistance in patients with chronic lymphocytic leukaemia. Here, the authors present crystal structures and biochemical analyses of venetoclax bound to BCL-2 and the G101V mutant ...
Richard W. Birkinshaw, Jia-nan Gong, Cindy S. Luo, Daisy Lio, Christine A. White, Mary Ann Anderson, Piers Blombery, Guillaume Lessene, Ian J. Majewski, Rachel Thijssen, Andrew W. Roberts, David C. S. Huang, Peter M. Colman, Peter E. Czabotar   +13 more
doaj   +1 more source

Leveraging venetoclax‐induced autophagy to enhance AUTAC‐mediated Mcl1 degradation and overcome resistance in acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Ahmed M. Elshazly, Nayyerehalsadat Hosseini, Janakiram R. Vangala, Xiaoyan Hu, Steven Grant, Senthil K. Radhakrishnan   +5 more
wiley   +1 more source